PuSH - Publication Server of Helmholtz Zentrum München: An accelerated dose escalation with a grass pollen allergoid is safe and well-tolerated: A randomized open label phase II trial.

Navigation

Home

Deutsch

Research

Advanced Search

Browse by ...

... Journal

... Publication Type

... Research Data

... Publication Year

Publication overview

Support & Contact

Contact persons

Help

Data protection

Chaker, A. ; Al-Kadah, B.* ; Luther, U.* ; Neumann, U.* ; Wagenmann, M.*

An accelerated dose escalation with a grass pollen allergoid is safe and well-tolerated: A randomized open label phase II trial.

Clin. Transl. Allergy 6:4 (2015)

Publ. Version/Full Text

DOI

PMC

	Open Access Gold

Abstract
Metrics
Extra information

BACKGROUND: The number of injections in the dose escalation of subcutaneous immunotherapy (SCIT) is small for some currently used hypoallergenic allergoids, but can still be inconvenient to patients and can impair compliance. The aim of this trial was to compare safety and tolerability of an accelerated to the conventional dose escalation scheme of a grass pollen allergoid. METHODS: In an open label phase II trial, 122 patients were 1:1 randomized for SCIT using a grass pollen allergoid with an accelerated dose escalation comprising only 4 weekly injections (Group I) or a conventional dose escalation including 7 weekly injections (Group II). Safety determination included the occurrence of local and systemic adverse events. Tolerability was assessed by patients and physicians. RESULTS: Treatment-related adverse events were observed in 22 (36.1 %) patients in Group I and 15 (24.6 %) in Group II. Local reactions were reported by 18 patients in Group I and 11 in Group II. Five Grade 1 systemic reactions (WAO classification) were observed in Group I and 2 in Group II. Grade 2 reactions occurred 3 times in Group I and 2 times in Group II. Tolerability was rated as "good" or "very good" by 53 (86.9 %) patients in Group I and 59 (100 %) in Group II by investigators. Forty-eight patients in Group I (80.0 %) and 54 in Group II (91.5 %) rated tolerability as "good" or "very good". CONCLUSIONS: The dose escalation of a grass pollen allergoid can be accelerated with safety and tolerability profiles comparable to the conventional dose escalation.

Altmetric

Additional Metrics?

[➜Log in]

Edit extra informations Login

Publication type Article: Journal article

Document type Scientific Article

Corresponding Author

Keywords Accelerated Dose Escalation ; Allergoid ; Safety ; Subcutaneous Immunotherapy ; Tolerability; Immunotherapy Schedules; Subcutaneous Immunotherapy; Adherence; Efficacy; Extracts; Rhinitis; Asthma

e-ISSN 2045-7022

Journal Clinical and Translational Allergy

Quellenangaben Volume: 6, Issue: 1, Article Number: 4

Publisher BioMed Central

Publishing Place London

Non-patent literature Publications

Reviewing status Peer reviewed

Institute(s) Institute for Allergy Research (IAF)